These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 11577258

  • 21. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 22. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 01; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 23. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
    Juran NB.
    Am Heart J; 1999 Oct 01; 138(4 Pt 2):297-306. PubMed ID: 10502235
    [Abstract] [Full Text] [Related]

  • 24. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators.
    Am Heart J; 2001 Mar 01; 141(3):402-9. PubMed ID: 11231437
    [Abstract] [Full Text] [Related]

  • 25. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.
    J Am Coll Cardiol; 2010 Aug 03; 56(6):463-9. PubMed ID: 20670755
    [Abstract] [Full Text] [Related]

  • 26. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.
    Coons JC, Seybert AL, Saul MI, Kirisci L, Kane-Gill SL.
    Ann Pharmacother; 2005 Oct 03; 39(10):1621-6. PubMed ID: 16105872
    [Abstract] [Full Text] [Related]

  • 27. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
    Bajaj RR, Mohammad A, Hong T, Irfan A, Sharieff W, Bagnall A, Christie JA, Kutryk MJ, Chisholm RJ, Cheema AN.
    J Invasive Cardiol; 2010 Aug 03; 22(8):347-52. PubMed ID: 20679668
    [Abstract] [Full Text] [Related]

  • 28. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
    Vakili BA, Kaplan RC, Slater JN, Sherman W, Ravi KL, Green SJ, Sanborn TA, Brown DL.
    Am J Cardiol; 2003 Apr 15; 91(8):946-50. PubMed ID: 12686333
    [Abstract] [Full Text] [Related]

  • 29. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 30. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM, Califf RM, Topol EJ.
    J Am Coll Cardiol; 2000 Apr 20; 35(5):1103-15. PubMed ID: 10758948
    [Abstract] [Full Text] [Related]

  • 31. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 20; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 32. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
    Racine E.
    Am J Health Syst Pharm; 2002 Nov 01; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
    [Abstract] [Full Text] [Related]

  • 33. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
    De Luca G, Navarese E, Marino P.
    Eur Heart J; 2009 Nov 01; 30(22):2705-13. PubMed ID: 19875386
    [Abstract] [Full Text] [Related]

  • 34. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ, Kereiakes DJ.
    J Invasive Cardiol; 2002 Jul 01; 14(7):404-10. PubMed ID: 12082194
    [Abstract] [Full Text] [Related]

  • 35. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.
    J Invasive Cardiol; 2003 Jun 01; 15(6):319-23. PubMed ID: 12777670
    [Abstract] [Full Text] [Related]

  • 36. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
    Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ, TARGET Investigators.
    J Am Coll Cardiol; 2003 Oct 01; 42(7):1188-95. PubMed ID: 14522478
    [Abstract] [Full Text] [Related]

  • 37. Real-world safety and efficacy of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Casterella PJ, Revenaugh JR, Burke JL, Pearson RR, Bair TL, May HT, Horne B, Anderson JL, Muhlestein JB.
    J Invasive Cardiol; 2008 Mar 01; 20(3):94-8. PubMed ID: 18316822
    [Abstract] [Full Text] [Related]

  • 38. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Mar 01; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 39. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 40. Drip and ship: a new strategy for the treatment of acute coronary syndromes.
    Chadow HL, Hauptman RE, VanAuker M, Rafii SE, Gunsburg MY, Giarraffa L, Strom JA.
    J Thromb Thrombolysis; 2000 Aug 27; 10(1):77-82. PubMed ID: 10947917
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.